China NMPA Product Recall - Fully Automated Fluorescence Immunoassay Analyzer

The National Medical Products Administration (NMPA) in China has published information regarding a voluntary Class II recall initiated by bioMérieux Diagnostics (Shanghai) Co., Ltd. The recall, announced on August 11, 2017, concerns a fully automated fluorescence immunoassay analyzer, registered under CFDA Import Medical Device Registration No. 20143401946. The primary issue identified is a software malfunction within the affected product. This defect has the potential to generate incorrect test results, posing a risk to accurate diagnostic outcomes. In response to this critical defect, bioMérieux Diagnostics (Shanghai) Co., Ltd. proactively initiated a voluntary recall to address the problem. The regulatory framework for this action is overseen by the NMPA, which hosts the recall information. As a required action, the company is recalling specific models, specifications, and batch numbers of the affected analyzers. Detailed information is provided in the "Medical Device Recall Event Report Form" attachment, though the form itself is not included in this document excerpt. This voluntary recall aims to mitigate potential patient safety risks associated with inaccurate diagnostic readings due to the software malfunction, ensuring compliance with NMPA standards for medical device safety and efficacy.